Latest news and press releases about Allogene Therapeutics, Inc. (ALLO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
Price
| Price | $1.69 |
| Market Cap | $583M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.14 |
| EV / EBITDA | -4.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -50.04% |
| Return on Invested Capital | -34.79% |
| Return on Assets | -30.08% |
| Gross Margin | -699.35% |
| Operating Margin | -3886.14% |
| Net Margin | -3566.68% |
Related companies: ACHV · AVIR · CABA · CRBU · EDIT · HUMA · IMMP
Explore sector: Healthcare · Biotechnology
More sections of ALLO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks